novel pd-1 inhibitor and btk inhibitor combination: tislelizumab and zanubrutinib
Published 6 years ago • 469 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
2:04
imc-001: preliminary results of novel pd-l1 inhibitor for r/r extranodal nk/t cell lymphoma
-
3:51
novel agents in mzl: btkis, pi3k inhibitors, and immunotherapeutics
-
1:46
novel agent combinations for cll: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
-
1:50
novel treatment regimens under investigation for richter's transformation
-
1:21
overview of the role of non-covalent btk inhibitors in the era of covalent btk inhibitors
-
0:34
novel agents under investigation in mpns: mdm2, xpo1, and bet inhibitors
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
3:40
discovering the pd-1 checkpoint: winners of the 2014 william b. coley award for tumor immunology
-
4:22
discover versiti diagnostic labs, clinical trials and biomaterials | versiti
-
1:14
predicting patient response to btk inhibitors using novel approaches
-
1:22
novel agents in cll: acalabrutinib and zanubrutinib
-
1:32
novel btki strategies in indolent b-cell malignancies: pirtobrutinib for fl and mzl
-
1:14
novel inducers of apoptosis in double-refractory cll cells
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:35
phase i study of plx51107, a novel bet inhibitor, in combination with azacitidine in r/r mds and aml
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
1:05
combining ublituximab with the novel pi3k inhibitor tgr-1202 for cll
-
4:47
btk degradation as a novel therapeutic strategy for relapsed cns lymphoma
-
1:14
promising novel agents in aml: menin inhibitors
-
3:48
impressive data: zanubrutinib for waldenström’s macroglobulinemia